|
|
3260 Bayshore Blvd.
Brisbane, CA 94005 USA
phone:415-287-2300
fax:415-287-2456
|
|
| Symbol |
Private |
| Founded |
2000 |
| Employees |
|
|
|
| www.xdx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Molecular diagnostics to translate immune status into clinically actionable information. |
|
| Management |
| Pierre Cassigneul, President & CEO; Dr. James Yee, CMO; Jean-Frederic Viret, CFO |
| |
|
|
| |
|
| Keywords |
| molecular diagnostics, immune, heart transplant, non-invasive, rejection, advamed |
|
|
|
| Description |
|
XDx develops molecular diagnostics that translate an individual's immune status into clinically actionable information. |
|
| Products / Services |
AlloMap molecular expression testing is a non-invasive method for determining the risk of rejection in heart transplant recipients. The test translates the complex signals of the immune system's multiple genes and pathways, specifically those associated with heart transplant rejection, into an objective, actionable score.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
